Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.60 |
| ▸ | KDR | P35968 | 8/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | KIF5B | P33176 | 1/20 | 0.60 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578463 | 0.90 | EGFR (0.62) | EGFRKDRRETKIF5BFBP1 | |
| SCHEMBL4577412 | 0.89 | KDR (0.59) | EGFRKDRRETKIF5BTDP1 | |
| SCHEMBL5097637 | 0.87 | KDR (0.60) | EGFRKDRABCG2 | |
| SCHEMBL4579881 | 0.86 | EGFR (0.50) | EGFRKDRRETKIF5BFBP1 | |
| SCHEMBL4578621 | 0.86 | EGFR (0.47) | EGFRKDRRETKIF5BFBP1 | |
| SCHEMBL30820491 | 0.86 | EGFR (0.63) | EGFRKDRRETKIF5BFBP1 | |
| SCHEMBL4579035 | 0.86 | EGFR (0.51) | EGFRKDRRETKIF5BFBP1 | |
| SCHEMBL4579543 | 0.85 | EGFR (0.56) | EGFRKDRRETKIF5BFBP1 | |
| SCHEMBL4578156 | 0.85 | ABCG2 (0.49) | EGFRKDRRETKIF5BABCG2 | |
| SCHEMBL4579295 | 0.85 | KDR (0.64) | EGFRKDRRETKIF5BFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | disclosed |
| CN-101304978-B | Quinazoline derivative as multi-component inhibitor, pharmaceutical composition and application | HANMI PHARM IND CO LTD | 2012-12-26 | — | — | CN | disclosed |
| CN-102731485-A | 4-(substituted phenylamino)quinazoline derivative, its preparation method, pharmaceutical composition and application | QILU PHARMACEUTICAL CO LTD | 2012-10-17 | — | — | CN | disclosed |
| WO-2012136099-A1 | 4-(SUBSTITUTED PHENYLAMINO)QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 齐鲁制药有限公司 (CN) | 2012-10-11 | — | — | WO | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| CN-101304978-A | Quinazoline derivatives as multiplex inhibitors and process for their preparation | HANMI PHARM IND CO LTD (KR) | 2008-11-12 | — | — | CN | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055513-A1 | QUINAZOLINE DERIVATIVES AS A SIGNAL TRANSDUCTION INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | EGFR 955/4885KDR 1226/4885RET 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.